MedTrace Logo

Study of Covalently Closed Circular DNA (cccDNA) in Liver Transplant Patients With B Virus Markers

NCT02602847 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-01-11

No results posted yet for this study

Summary

The aim of this study is to validate in the context of liver transplantation, the interest of the cccDNA assay technique developed by the team of Professor Zoulim (INSERM U1052) on liver biopsy and correlate this assay cccDNA in hepatitis B virus (HBV) viral load and serum liver through several groups of patients at transplantation (on graft and native liver explant) and after transplantation.

Conditions

  • Liver Transplantation

Interventions

BIOLOGICAL

cccDNA assay on liver biopsy

cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Fabien ZOULIM, MD, PhD · Service d'Hépatologie, Hôpital Croix-Rousse, Hospices Civils de Lyon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02602847 on ClinicalTrials.gov